Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide-MHC Interactions
Geir Åge Løset1, Gøril Berntzen2, Terje Frigstad2
1Nextera AS , Oslo , Norway ; Centre for Immune Regulation, Oslo University Hospital, University of Oslo , Oslo , Norway ; Department of Biosciences, University of Oslo , Oslo , Norway.
Abstract:
Cancer immunotherapy has finally come of age, demonstrated by recent progress in strategies that engage the endogenous adaptive immune response in tumor killing. Occasionally, significant and durable tumor regression has been achieved. A giant leap forward was the demonstration that the pre-existing polyclonal T cell repertoire could be re-directed by use of cloned T cell receptors (TCRs), to obtain a defined tumor-specific pool of T cells. However, the procedure must be performed with caution to avoid deleterious cross-reactivity. Here, the use of engineered soluble TCRs may represent a safer, yet powerful, alternative. There is also a need for deeper understanding of the processes that underlie antigen presentation in disease and homeostasis, how tumor-specific peptides are generated, and how epitope spreading evolves during tumor development. Due to its plasticity, the pivotal interaction where a TCR engages a peptide/MHC (pMHC) also requires closer attention. For this purpose, phage display as a tool to evolve cloned TCRs represents an attractive avenue to generate suitable reagents allowing the study of defined pMHC presentation, TCR engagement, as well as for the discovery of novel therapeutic leads. Here, we highlight important aspects of the current status in this field.
Insights
Cancer immunotherapy harnesses the immune system to fight tumors. Engineered T cell receptors (TCRs) offer a promising approach, with soluble TCRs potentially providing a safer alternative for targeted cancer treatment.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Cancer immunotherapy has advanced significantly, utilizing the adaptive immune response for tumor elimination.
- T cell receptors (TCRs) can be engineered to redirect T cells against specific tumor antigens, but cross-reactivity is a concern.
- Understanding antigen presentation and TCR-pMHC interactions is crucial for improving cancer treatments.
Purpose of the Study:
- To explore engineered soluble TCRs as a safer alternative to cloned TCRs for cancer immunotherapy.
- To highlight the need for a deeper understanding of T cell receptor (TCR) and peptide/MHC (pMHC) interactions.
- To discuss the utility of phage display in evolving TCRs for therapeutic lead discovery and studying pMHC interactions.
Main Methods:
- Review of current strategies in cancer immunotherapy involving T cell receptor engineering.
- Discussion of phage display technology for evolving cloned TCRs.
- Analysis of peptide/MHC (pMHC) interactions and TCR engagement.
Main Results:
- Engineered T cell receptors (TCRs) show potential for redirecting T cells against tumors.
- Soluble TCRs may offer a safer alternative by mitigating cross-reactivity issues.
- Phage display is a valuable tool for generating TCR reagents for research and therapeutic development.
Conclusions:
- Cancer immunotherapy is a rapidly advancing field with significant therapeutic potential.
- Engineered TCRs, particularly soluble variants, represent a promising avenue for targeted cancer therapy.
- Further research into TCR-pMHC interactions and the application of phage display is essential for future advancements.
